Characterization of a Neuraminidase-Deficient Influenza A Virus as a Potential Gene Delivery Vector and a Live Vaccine

Journal of Virology

Volumn 78, Issue 6, 2004, Pages 3083-3088

  Shinya, Kyoko ^a   Fujii, Yutaka ^b   Ito, Hiroshi ^c   Ito, Toshihiro ^c   Kawaoka, Yoshihiro ^a,d,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; INFLUENZA VACCINE; LIVE VACCINE; SIALIC ACID; SIALIDASE; VIRUS RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHIOLE; CONTROLLED STUDY; DRUG SCREENING; EPITHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; INFLUENZA VIRUS VECTOR; LUNG ALVEOLUS; MOUSE; NONHUMAN; NOSE MUCOSA; OPEN READING FRAME; PRIORITY JOURNAL; VIRION; VIRUS ATTENUATION; VIRUS MUTANT;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MUTATION; NEURAMINIDASE; VACCINES, ATTENUATED;

EID: 1542287451     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.6.3083-3088.2004     Document Type: Article

References (44)

1. Boivin, G., N. Goyette, and H. Bernatchez. 2002. Prolonged excretion of amantadine-resistant influenza A virus quasispecies after cessation of antiviral therapy in an immunocompromised patient. Clin. Infect. Dis. 34:e23-e25.
2. Bramson, J. L., and Y. H. Wan. 2002. The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin. Biol. Ther. 2:75-85.
3. Capua, I., C. Terregino, G. Cattoli, F. Mutinelli, and J. F. Rodriguez. 2003. Development of a DIVA (differentiating infected from vaccinated animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza. Avian Pathol. 32:47-55.
4. Castrucci, M. R., S. Hou, P. C. Doherty, and Y. Kawaoka. 1994. Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J. Virol. 68:3486-3490.
5. Cha, T. A., K. Kao, J. Zhao, P. E. Fast, P. M. Mendelman, and A. Arvin. 2000. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. Microbiol. 38:839-845.
6. Chen, Z., T. Yoshikawa, S., Kadowaki, Y., Hagiwara, K., Matsuo, H., Asanuma, C., Aizawa, T., Kurata, and S. Tamura. 1999. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 80:2559-2564.
7. Edwards, K. M., W. D. Dupont, M. K. Westrich, W. D. Plummer, Jr., P. S. Palmer, and P. F. Wright. 1994. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169:68-76.
8. Ferko, B., D. Katinger, A. Grassauer, A. Egorov, J. Romanova, B. Niebler, H. Katinger, and T. Muster. 1998. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in genital tract. J. Infect. Dis. 178:1359-1368.
9. Fujii, Y., H. Goto., T. Watanabe, T. Yoshida, and Y. Kawaoka. 2003. Selective incorporation of influenza virus RNA segments into virions. Proc. Natl. Acad. Sci. USA 100:2002-2007.
10. Gao, P., S. Watanabe, T. Ito, H. Goto, K. Wells, M. McGregor, A. J. Cooley, and Y. Kawaoka. 1999. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J. Virol. 73:3184-3189.
11. García-Sastre, A., T. Muster, W. S. Barclay, N. Percy, and P. Palese. 1994. Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus. J. Virol. 68:6254-6261.
12. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antivir. Res. 53:47-61.
13. + T cells ameliorates antigen-induced eosinophilic inflammation. A novel high-dose tolerance in the trachea. Am. J. Respir. Cell Mol. Biol. 21:268-274.
14. Hayden, F. G. 2001. Perspectives on antiviral use during pandemic influenza. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:1877-1884.
15. Hermiston, T. W., and I. Kuhn. 2002. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 9:1022-1035.
16. Hughes, M. T., M. Matrosovich, M. E. Rodgers, M. McGregor, and Y. Kawaoka. 2000. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J. Virol. 74:5206-5212.
17. Hughes, M. T., M. McGregor, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2001. Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity. J. Virol. 75:3766-3770.
18. Johansson, B. E., and E. D. Kilbourne. 1994. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc. Natl. Acad. Sci. USA 91:2358-2361.
19. Liu, C., and G. M. Air. 1993. Selection and characterization of a neuraminidase-minus mutant of infuenza virus and its rescue by cloned neuraminidase genes. Virology 194:403-407.
20. Liu, C., M. C. Eichelberger, R. W. Compans, and G. M. Air. 1995. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 69:1099-1106.
21. Luytjes, W., M. Krystal, M. Enami, J. D. Pavin, and P. Palese. 1989. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59:1107-1113.
22. Lyles, D. S. 2000. Cytopathogenesis and inhibition of host gene expression by RNA viruses. Microbiol. Mol. Biol. Rev. 64:709-724.
23. Mozdzanowska, K., K. Maiese, M. Furchner, and W. Gerhard. 1999. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254:138-146.
24. Muster, T., B. Ferko, A. Klima, M. Purtscher, A. Trkola, P. Schulz, A. Grassauer, O. G. Engelhardt, A. García-Sastre, P. Palese, et al. 1995. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69:6678-6686.
25. Nedyalkova, M. S., F. G. Hayden, R. G. Webster, and L. V. Gubareva. 2002. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as marker of reduced dependence on NA. J. Infect. Dis. 185:591-598.
26. Neumann, G., A. Zobel, and G. Hobom. 1994. RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 202:477-479.
27. Neumann, G., and G. Hobom. 1995. Mutational analysis of influenza virus promoter elements in vivo. J. Gen. Virol. 76:1709-1717.
28. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96:9345-9350.
29. Neumann, G., T. Watanabe, and Y. Kawaoka. 2000. Plasmid-driven formation of influenza virus-like particles. J. Virol. 74:547-551.
30. Palese, P., and R. W. Compans. 1976. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. 33:159-163.
31. Palese, P., F. Zavala, T. Muster, R. S. Nussenzweig, and A. Garcia-Sastre. 1997. Development of novel influenza virus vaccines and vectors. J. Infect. Dis. 176:S45-S49.
32. Percy, N., W. S. Barclay, A. García-Sastre, and P. Palese. 1994. Expression of a foreign protein by influenza A virus. J. Virol. 68:4486-4492.
33. Piedra, P. A., L. Yan, K. Kotloff, K. Zangwill, D. I. Bernstein, J. King, J. Treanor, F. Munoz, M. Wolff, I. Cho, P. M. Mendelman, J. Cordova, and R. B. Belshe. 2002. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110:662-672.
34. Romano, G., P. Micheli, C. Pacilio, and A. Giordano. 2000. Latest development in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18:19-39.
35. Saito, R., H. Oshitani, H. Masuda, and H. Suzuki. 2002. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J. Clin. Microbiol. 40:84-88.
36. Schultz-Cherry, S., and V. S. Hinshaw. 1996. Influenza virus neuraminidase activates latent transforming growth factor β. J. Virol. 70:8624-8629.
37. Shiraishi, K., K. Mitamura, Y. Sakai-Tagawa, H. Goto, N. Sugaya, and Y. Kawaoka. 2003. High frequency of resistant viruses harboring different mutations in amantadine treated children with influenza. J. Infect. Dis. 188:57-61.
38. Strobel, I., M. Krumbholz, A. Menke, E. Hoffmann, P. R. Dunbar, A. Bender, G. Hobom, A. Steinkasserer, G. Schuler, and R. Grassmann. 2000. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. Hum. Gene Ther. 11:2207-2218.
39. Wahl, S. M. 1992. Transforming growth factor beta (TGF-b) in inflammation a cause and a cure. J. Clin. Immunol. 12:61-74.
40. Watanabe, T., S. Watanabe, G. Neuman, H. Kida, and Y. Kawaoka. 2002. Immunogenicity and protective efficacy of replication incompetent influenza virus-like particles. J. Virol. 76:767-773.
41. Wickham, T. J. 2003. Ligand-directed targeting of genes to the site of disease. Nat. Med. 9:135-139.
42. Wright, P. F., and R. G. Webster. 2001. Orthomyxoviruses, p. 1533-1579. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, Pa.
43. Zheng, H., P. Palese, and A. Garcia-Sastre. 2000. Antitumor properties of influenza virus vectors. Cancer Res. 60:6972-6976.
44. Zhou, Y., M. Konig, G. Hobom, and E. Neumeier. 1998. Membrane-anchored incorporation of a foreign protein in recombinant influenza virions. Virology 246:83-94.